Firefly Neuroscience stock surges 47.7% on AI-powered ADHD subtype diagnosis breakthrough

Firefly Neuroscience Stock Jumps on ADHD Diagnostic Breakthrough

Firefly Neuroscience saw its stock surge 47.7% to $2.57 on Friday following a significant announcement about advances in objective brain-based ADHD diagnosis tools 1

1

. The company revealed research progress using its AI-powered EEG technology to potentially distinguish between the three main ADHD subtypes: hyperactive-impulsive, inattentive, and combined presentations. Trading on NASDAQ under the ticker AIFF, the company's shares entered overbought territory with its RSI surging above 70, reflecting strong investor enthusiasm for the development 1

1

.

EEG Technology Targets $10 Billion ADHD Treatment Market

The announcement carries weight because ADHD diagnosis currently relies on symptom-based assessments rather than objective biological markers. Firefly Neuroscience is targeting a U.S. ADHD treatment market estimated at over $10 billion, with more than 22 million Americans diagnosed with the condition 2

2

. The company's FDA-510(k)-cleared Evoke System uses Resting EEG and Cognitive EEG, also known as ERP, to collect brain scans that may identify neural biomarkers tied to specific ADHD presentations 1

1

2

2

. This approach could complement traditional checklists with brain-based data, helping clinicians make more informed dosage decisions and monitor whether interventions are working at the neurological level.

Neural Biomarkers Enable Personalizing Treatment Approaches

Gil Issachar, Chief Technology Officer of Firefly Neuroscience, emphasized the potential for ADHD subtype research to transform clinical practice. "Firefly's EEG/ERP platform can leverage subtype-specific biomarker profiles to inform personalized treatment recommendations, potentially improving outcomes for the millions currently on generalized ADHD treatment plans," Issachar stated 2

2

. The technology also enables ongoing treatment monitoring, allowing clinicians to objectively track intervention efficacy at the neurological level. This represents a shift from subjective observation to data-driven brain analytics that could reshape how ADHD care is delivered across psychiatric and neurological conditions.

Building a Brain Foundation Model With NVIDIA Acceleration

The biomarker discovery advances Firefly's broader mission to build the world's first EEG/ERP brain foundation model, currently being trained on a repository of over 191,000 brain scans 2

2

. The company has secured access to NVIDIA GPU acceleration to power next-generation EEG/ERP processing, positioning it to scale its AI capabilities. Firefly's methodology draws support from prior peer-reviewed research, including a study published in Frontiers in Psychiatry that demonstrated the diagnostic utility of EEG-based brain activity flow pattern analysis in ADHD patients 2

2

. As the company continues to expand its dataset and refine its algorithms, investors and clinicians will be watching whether this approach can deliver measurable improvements in diagnostic accuracy and treatment outcomes for patients who have long relied on generalized care protocols.